Subconjunctival Bevacizumab and Recurrent Pterygium

Phase 2/3 Completed 36 enrolled Instituto de Olhos de Goiania

NaSingle-groupOpen-labelTreatment

Summary

A study to research whether subconjunctival bevacizumab injection may potentially suppress neovascularization in pterygium, retarding and decreasing the size of recurrent pterygium.

Timeline

Start: 2012-02
Primary completion: 2012-07
Completion: 2012-09

Publications

Stival LR, Lago AM, Figueiredo MN, Bittar RH, Machado ML, Nassaralla Junior JJ. Efficacy and safety of subconjunctival bevacizumab for recurrent pterygium. Arq Bras Oftalmol. 2014 Jan-Feb;77(1):4-7. doi: 10.5935/0004-2749.20140003.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bevacizumab	Monoclonal antibody	0.5 ml	Other

Subconjunctival Bevacizumab and Recurrent Pterygium

Summary

Timeline

Publications

Drugs

Indications